| Metric | Q2 2026 actual | Comparison | Read-through |
|---|---|---|---|
| Sales | $250.0M | $176.1M a year ago; published consensus $237.5M | Above expectation (Income Statement) |
| Adjusted diluted EPS | $0.21 | $0.10 a year ago; published consensus $0.19 | Above expectation (Adjusted Net Income reconciliation) |
| Adjusted EBITDA | $53.1M | $41.9M a year ago | +27%, but within management’s quarterly range (Adjusted EBITDA reconciliation) |
| Full-year Adjusted EBITDA outlook | $195M–$207M | Previous $180M–$195M | Headline raise; acquisition contribution matters (2026 Outlook) |
| Adjusted EBITDA margin | 21.2% | 23.8% a year ago | Down 2.6 percentage points despite higher sales (Adjusted EBITDA reconciliation) |
| Net leverage | 2.0x | 1.2x at December 31, 2025 | Higher after acquisition funding (Net Debt and Leverage table) |
The quarter cleared the published bar, not just an easy year-ago comparison. Sales were about $12.5M above the published $237.5M expectation, while adjusted EPS of $0.21 exceeded the published $0.19 estimate. That makes the operating result a real, if modest, upside surprise; $53.1M of adjusted EBITDA was also 27% higher year over year.
The guidance increase is positive, but the headline overstates the organic upgrade. Full-year adjusted EBITDA moves to $195M–$207M from $180M–$195M. However, the legacy business range only raises its low end to $185M while retaining the $195M high end; the acquired Calabrian business is expected to supply $10M–$12M in second-half EBITDA. In other words, first-half execution improved the floor, but most of the consolidated increase reflects a transaction that had already closed rather than a broad reset of the pre-acquisition outlook.
Top-line growth was much stronger than profit growth. Sales rose 42%, but adjusted EBITDA rose 27% and adjusted EBITDA margin fell to 21.2% from 23.8%. About $55M of the sales increase came from sulfur-cost pass-through, which inflates revenue without producing equivalent margin; higher manufacturing, inflation, and transportation costs also weighed on conversion. The demand backdrop for regenerated acid remains favorable, but management still expects lower virgin-acid sales in the second half versus 2025 and flags softer industrial demand as a risk (Financial Highlights; Adjusted EBITDA reconciliation; 2026 Outlook).
Cash generation improved, but the balance sheet absorbed the acquisition. Six-month operating cash flow from continuing operations more than doubled to $55.2M, and adjusted free cash flow turned positive at $12.8M. Yet cash fell to $87.8M from $197.2M, net debt increased to $409.3M from $199.9M, and leverage rose to 2.0x following the $100M term-loan increase tied to Calabrian. The result is a stronger earnings and cash-flow profile, offset by less balance-sheet cushion and an integration burden that now matters to the full-year outcome (Cash Flow statement; Balance Sheet; Net Debt and Leverage table).
Read the original 8-K on SEC EDGAR ↗